Cancers最新文献

{"title":"Changes in Cancer Care for Patients Aged 80 and Above: A Cohort Study from Samsung Comprehensive Cancer Center in South Korea.","authors":"Seung Tae Kim, Danbee Kang, Seok Jin Kim, Jun Ho Lee, Hong Kwan Kim, Yong Beom Cho, Yong Han Paik, Seok Won Kim, Byong Chang Jeong, Ho Jun Seol, Man Ki Chung, Kyu Taek Lee, Kihyun Kim, Sung-Wook Seo, Jeong-Won Lee, Hee Chul Park, Dong Wook Shin, Juhee Cho, Won Kim, Jeeyun Lee, Woo Yong Lee","doi":"10.3390/cancers17122017","DOIUrl":"10.3390/cancers17122017","url":null,"abstract":"<p><p><b>Background/Objectives:</b> With an estimated 70% of new cancer diagnoses expected to be in older adults within the next decade, cancer care for this population has attracted increasing global attention. Additionally, older patients are less likely to receive optimal cancer treatments. <b>Methods:</b> This retrospective cohort study utilized data from the Samsung Medical Center Cancer Registry, which includes patients diagnosed with cancer between 2008 and 2022. A 15-year cohort analysis was conducted to examine trends and survival outcomes by cancer type and stage in patients aged 80 years and older. <b>Results:</b> Among 301,055 patients with cancer, 13,111 (4.4%) were aged 80 years or older at diagnosis. The proportion of patients in this age group increased from 2.4% in 2008 to 5.8% in 2022. The most prevalent cancers in patients aged ≥80 years were lung (18.9%), stomach (15.3%), and colorectal cancer (13.8%). Among individuals with localized or regional-stage disease, the 5-year survival rate was 49.66% in those aged ≥80 years compared to 81.46% in younger patients (HR = 1.41; 95% CI = 1.35, 1.46). For distant-stage disease, survival was lower, at 10.53% in patients aged ≥80 years versus 27.61% in those aged <80 (HR = 1.14; 95% CI = 1.10, 1.19). Among patients aged 80 years and older, 55% received anti-cancer treatment, with the proportion increasing from 54.5% in 2008 to 60.3% in 2021. This increase was particularly notable in individuals with distant-stage disease. Additionally, the proportion of clinical trial participants aged ≥80 years exhibited an upward trend. Patients in this age group who underwent treatment had significantly improved survival compared to those who did not, in both localized or regional disease (HR = 0.45; 95% CI = 0.42, 0.49) and distant disease (HR = 0.58; 95% CI = 0.53, 0.62). <b>Conclusions:</b> The findings from this cohort of the SMC Cancer Registry highlight key trends, including a rising number of patients aged ≥80 years and an increasing proportion receiving treatment, particularly after 2020, when more than 60% received therapy. Furthermore, survival benefits associated with treatment were comparable to those observed in younger patients across all cancer types.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 12","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12191012/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144494714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Closer Look at Radiation Exposure During Percutaneous Cryoablation for T1 Renal Tumors.","authors":"Luna van den Brink, Michaël M E L Henderickx, Otto M van Delden, Harrie P Beerlage, Daniel Martijn de Bruin, Patricia J Zondervan","doi":"10.3390/cancers17122016","DOIUrl":"10.3390/cancers17122016","url":null,"abstract":"<p><p><b>Introduction:</b> Percutaneous cryoablation (PCA) can be a valid alternative to partial nephrectomy for patients with cT1a renal tumors. A potential disadvantage of PCA is radiation exposure for patients, though the exact significance of this is unknown. This study aims to uncover the degree of radiation exposure during PCA and what factors are of influence. <b>Methods:</b> This is a retrospective analysis of a prospectively maintained database of patients who underwent CT-guided PCA for cT1 renal cell carcinoma (RCC) between January 2014 and September 2024. The median effective dose (mSV) of PCA was calculated and compared to the expected cumulative radiation exposure during follow-up. Multivariate linear regression was performed to identify factors predictive of higher radiation exposure (mSV). <b>Results</b>: A total of 164 PCAs were performed, with radiation data available for 133 cases. Mean age was 65 (±11) years and the mean tumor diameter was 28 (±9.6) mm. Median effective dose of the CA procedures was 26 mSV (IQR 18-37). The estimated cumulative effective dose of follow-up CT scans according to 2016 and 2024 European Association of Urology guidelines was 158 (IQR 117-213) and 105 mSV (IQR 78-142), respectively. Multivariate linear regression analysis identified BMI (OR 1.723, <i>p</i> < 0.001), the number of needles used (OR 4.060, <i>p</i> < 0.001), and the necessity for additional procedures (OR 8.056, <i>p</i> < 0.001) as significant predictors of a higher effective dose. <b>Conclusions:</b> We found a median effective dose of 26 mSV for PCA, which is relatively low compared to the cumulative radiation exposure associated with CT scans during follow-up of patients post-ablation according to the guidelines. Furthermore, increased BMI, a higher number of required needles and the execution of additional procedures are all associated with a higher effective dose.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 12","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12191335/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144494755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Clinical Feasibility and Safety of 1.5 T MR-Guided Daily Adapted Radiotherapy in 1000 Patients: A Real-World Large Experience of an Early-Adopter Center.","authors":"Chiara De-Colle, Michele Rigo, Andrea Gaetano Allegra, Luca Nicosia, Niccolò Giaj-Levra, Edoardo Pastorello, Francesco Ricchetti, Carolina Orsatti, Andrea Romei, Nicola Bianchi, Riccardo Filippo Borgese, Antonio De Simone, Davide Gurrera, Stefania Naccarato, Gianluisa Sicignano, Ruggero Ruggieri, Filippo Alongi","doi":"10.3390/cancers17122012","DOIUrl":"10.3390/cancers17122012","url":null,"abstract":"<p><strong>Purpose/objective: </strong>The clinical implementation of MR-guided radiotherapy on MR-linacs (MRL) hasrapidly increased in recent years. The advantages represented by the MR-based daily online plan adaptation and real-time monitoring have been exploited for different tumor sites. Nevertheless, some concerns remain, mainly related to the longer treatment time and limited patient eligibility. We report here the experience of our center, where a 1.5T MRL was clinically implemented in 2019 and, since then, more than 1200 patients have been treated.</p><p><strong>Material and methods: </strong>The first 1000 patients treated at the MRL in our department were selected. Technical information such as treatment time and adaptive technic have been prospectively recorded, while toxicity data were retrospectively collected.</p><p><strong>Results: </strong>Between October 2019 and June 2024, 1000 patients for a total of 1061 treatment courses were included. Prostate and prostate bed were irradiated in 57.1% and 10.2% of the cases, respectively, including regional pelvic lymphnodes in 4.7%. Other frequent treated sites were lymph node metastases, pancreas and liver. The most frequent prescribed doses were 36.25 Gy (31%), 35 Gy (28.3%) and 30 Gy (9.4%) in five fractions. On a total of 9076 administered fractions, 80.8% were performed with adapt-to-shape and 19.2% with adapt-to-position method. The mean in-room time was 38 min (range, 18-103), with 74.4% of patients completing the session within 40 min. Acute grade (G) 3 toxicity was recorded in 1.6% of the cases, while, on a total of 858 patients available for late toxicity, G3 was recorded in 0.3% of the cases, with no >G3.</p><p><strong>Conclusions: </strong>Our real-world experience of an early-adopter center confirms that MRL treatments are feasible for different tumor entities in several anatomical sites. We showed that most of the patients could be treated within 40 min and showed low toxicity rates. Protocols for dose escalation and margin reduction, by adopting new comprehensive motion monitoring strategies, are under development.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 12","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12191406/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144494807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrative Molecular and Immune Profiling in Advanced Unresectable Melanoma: Tumor Microenvironment and Peripheral PD-1+ CD4+ Effector Memory T-Cells as Potential Markers of Response to Immune Checkpoint Inhibitor Therapy.","authors":"Manuel Molina-García, María Jesús Rojas-Lechuga, Teresa Torres Moral, Francesca Crespí-Payeras, Jaume Bagué, Judit Mateu, Nikolaos Paschalidis, Vinícius Gonçalves de Souza, Sebastian Podlipnik, Cristina Carrera, Josep Malvehy, Rui Milton Patricio da Silva-Júnior, Susana Puig","doi":"10.3390/cancers17122022","DOIUrl":"10.3390/cancers17122022","url":null,"abstract":"<p><p><b>Background/Objectives:</b> Immune checkpoint inhibitors (ICIs) have revolutionized advanced melanoma treatment, yet many patients fail to achieve sustained clinical benefit. Several biomarkers, including tumor microenvironment (TME) signature, PD-1/PD-L1 expression, and IFN-γ signaling, have been proposed. However, robust predictive markers remain elusive. This study aimed to identify molecular markers of response by analyzing tumor and peripheral immune signatures. <b>Methods:</b> This study analyzed 21 advanced melanoma patients treated with ICIs. Formalin-fixed, paraffin-embedded tumors underwent RNA-sequencing targeting 1392 immuno-oncology probes. Genes significantly associated with progression-free survival (PFS) by log-rank test underwent hierarchical clustering analysis (HCA). Differential expression and xCell analyses were then performed on the resulting clusters. Cox multivariate analysis was applied to identify independent PFS predictors. Pre-treatment peripheral blood mononuclear cells were analyzed by mass cytometry, followed by FlowSOM and UMAP clustering. <b>Results:</b> Fifty-five genes significantly associated with PFS identified two molecular clusters via HCA. Cluster A demonstrated prolonged PFS (59.4 vs. 2.4 months, <i>p</i> = 0.0004), while Cluster B was characterized by downregulated IFN-γ signaling, antigen presentation pathways, and reduced immune score. Multivariate Cox analysis confirmed molecular cluster as an independent PFS predictor (<i>p</i> < 0.001). Mass cytometry revealed higher frequencies of circulating PD-1+ CD4+ effector memory (EM) T subpopulations among responders. <b>Conclusions:</b> This study highlights the potential role of molecular and immune profiling in predicting ICI response in advanced melanoma. The identification of distinct molecular clusters underscores significant TME heterogeneity, with immune-cold tumor clusters associated with poorer outcomes. Furthermore, circulating PD-1+ T subpopulations emerged as potential markers of ICI response, suggesting their value in improving patient stratification.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 12","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12190280/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144494834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genome-Wide cfDNA Methylation Profiling Reveals Robust Hypermethylation Signatures in Ovarian Cancer.","authors":"Simone Karlsson Terp, Karen Guldbrandsen, Malene Pontoppidan Stoico, Lasse Ringsted Mark, Anna Poulsgaard Frandsen, Karen Dybkær, Inge Søkilde Pedersen","doi":"10.3390/cancers17122026","DOIUrl":"10.3390/cancers17122026","url":null,"abstract":"<p><p><b>Background:</b> Ovarian cancer remains the most lethal gynecological cancer, primarily due to its asymptomatic nature in early stages and consequent late diagnosis. Early detection improves survival, but current biomarkers lack sensitivity and specificity. Cell-free DNA (cfDNA) released from tumor cells captures tumor-associated epigenetic alterations and represents a promising source for minimally invasive biomarkers. Among these, aberrant DNA methylation occurs early in tumorigenesis and may reflect underlying disease biology. This study aimed to investigate genome-wide cfDNA methylation profiles in patients with ovarian cancer, benign ovarian conditions, and healthy controls to identify cancer-associated methylation patterns that may inform future biomarker development. <b>Results:</b> We performed genome-wide cfDNA methylation profiling using cell-free methylated DNA immunoprecipitation sequencing (cfMeDIP-seq) on plasma samples from 40 patients with high-grade serous ovarian carcinoma, 38 patients with benign ovarian conditions, and 38 healthy postmenopausal women. A total of 536 differentially methylated regions (DMRs) were identified between ovarian cancer and controls (n = 76), with 97% showing hypermethylation in ovarian cancer. DMRs were enriched in CpG islands and gene bodies and depleted in repetitive elements, consistent with known cancer-associated methylation patterns. Fifteen genes showed robust hypermethylation across analyses. These genes exhibited methylation across intronic, exonic, and upstream regulatory regions. Separate comparisons of ovarian cancer to each control group (benign and healthy) supported the reproducibility of these findings. Gene Ontology enrichment analysis revealed enrichment in gland development, embryonic morphogenesis, and endocrine regulation, suggesting biological relevance to ovarian tumorigenesis. <b>Conclusions:</b> This study identifies consistent cfDNA hypermethylation patterns in ovarian cancer, affecting genes involved in developmental regulation and hormone-related processes. Our findings underscore the potential of cfMeDIP-seq for detecting tumor-specific methylation signatures in plasma and highlight these 15 hypermethylated genes as biologically relevant targets for future studies on cfDNA methylation in ovarian cancer.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 12","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12190857/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144494798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fluorescence Guidance in Glioma Surgery: A Narrative Review of Current Evidence and the Drive Towards Objective Margin Differentiation.","authors":"Matthew Elliot, Silvère Ségaud, Jose Pedro Lavrador, Francesco Vergani, Ranjeev Bhangoo, Keyoumars Ashkan, Yijing Xie, Graeme J Stasiuk, Tom Vercauteren, Jonathan Shapey","doi":"10.3390/cancers17122019","DOIUrl":"10.3390/cancers17122019","url":null,"abstract":"<p><p>Fluorescence-guided surgery (FGS) was pioneered for glioma and is now established as the standard of care. Gliomas are infiltrative tumours with diffuse margins. FGS provides improved intra-operative identification of tumour margins based on tumour-specific emission visible to the operating surgeon, resulting in increased rates of gross total resection. Multiple fluorescence agents may be used including 5-ALA, fluorescein sodium, and indocyanine green (ICG). This review details the indication, required equipment, mechanism of action, evidence base, limitations, and regulatory issues for each fluorophore as utilised in current clinical practice. FGS for glioma is limited by a reliance on subjective interpretation of visible fluorescence, which is often not present in low-grade glioma (LGG) or at the infiltrative tumour margin. Consequently, there has been a drive to develop enhanced, objective FGS techniques utilising both quantitative fluorescence (QF) imaging systems and novel fluorophores. This review provides an overview of emerging QF imaging systems for FGS. The pipeline for novel fluorophore development is also summarised.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 12","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12190578/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144494792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of Massage Therapy in Breast Cancer Survivors with Mastectomy: Systematic Review.","authors":"Juan Rodríguez Mansilla, Ana Sánchez Díaz, Blanca González Sánchez, María Del Valle Ramírez-Durán, Elisa María Garrido Ardila, María Del Carmen Cilleros Sánchez, María Jiménez Palomares","doi":"10.3390/cancers17122023","DOIUrl":"10.3390/cancers17122023","url":null,"abstract":"<p><strong>Background: </strong>Mastectomy, a common treatment for breast cancer, often leads to complications such as pain, fibrosis, restricted mobility, lymphedema, reduced strength in the affected arm, and emotional distress. Non-pharmacological therapies, including massage therapy, offer a holistic approach to managing these symptoms. The aim of this study was to analyze the effects of massage therapy on the symptomatology in women post-mastectomy for breast cancer.</p><p><strong>Methods: </strong>A systematic review was conducted following PRISMA guidelines. Databases including PubMed, Cochrane, PEDro, Dialnet, Science Direct, and Scopus were searched for relevant studies published in English or Spanish over the past 16 years. The search was conducted in March 2025. Inclusion criteria encompassed controlled and uncontrolled clinical trials, quasi-experimental studies, retrospective analyses, and secondary trial analyses involving women aged 45-64 who received massage therapy as a complementary treatment.</p><p><strong>Results: </strong>Twenty-six studies involving 1522 participants were included. Interventions assessed were manual lymphatic drainage, myofascial release, foot massage, classical massage, and the Cyriax technique. The key findings demonstrated significant benefits, including improved range of motion, reduced arm circumference and lymphedema volume, enhanced quality of life, and increased relaxation.</p><p><strong>Conclusions: </strong>According to the results of this systematic review, massage therapy interventions can have a positive impact on the symptomatology in women post-mastectomy for breast cancer and may represent a suitable complementary approach to post-mastectomy breast cancer treatment.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 12","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12190418/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144494738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances in Molecular Imaging for Neuroendocrine Neoplasms.","authors":"Bradley Girod, Vikas Prasad","doi":"10.3390/cancers17122013","DOIUrl":"10.3390/cancers17122013","url":null,"abstract":"<p><p>Neuroendocrine neoplasms (NENs) represent a heterogenous group of tumors with significant inter- and intra-patient variability. Once considered to be rare, neuroendocrine neoplasms are being increasingly recognized through the advent of advanced diagnostic techniques, which may be contributing to the significant increase in the incidence and detection rate of these tumors. NENs can be classified into well differentiated and poorly differentiated neuroendocrine tumors (NETs) or neuroendocrine carcinomas (NECs). The proliferation rate of NETs can vary from Ki-67 1-55%. In addition, the SSTR expression can vary significantly. Because of this high \"heterogeneity\", their detection and characterization have become essential to disease management, leading to dual-tracer imaging, most commonly with FDG- and SSTR-targeted PET/CT. Because of the complexity of the disease, the optimal treatment of patients depends on a combination of imaging, serological biomarkers, and clinical information. There remains a significant portion of patients who do not respond as anticipated, and the management of their disease remains challenging with current techniques, necessitating the refinement of our technologies and the development of new ones. In addition to new biological targets, improved peptide vector targeting for the somatostatin receptor needs further development. This review aims to evaluate the existing imaging techniques utilized in the diagnosis, assessment, and treatment of NENs, as well as the emerging radiopharmaceuticals and technologies, which will expand our imaging repertoire as well as our management options.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 12","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12191301/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144494762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of Canine Models of Human Cancer: Overcoming Drug Resistance Through a Transdisciplinary \"One Health, One Medicine\" Approach.","authors":"Sara Gargiulo, Lidovina Vecchiarelli, Eleonora Pagni, Matteo Gramanzini","doi":"10.3390/cancers17122025","DOIUrl":"10.3390/cancers17122025","url":null,"abstract":"<p><strong>Introduction: </strong>Chemotherapy is a primary treatment option in human and veterinary oncology. Like humans, canine patients often develop drug resistance. Comparative oncology is gaining increasing interest, and spontaneous tumors of companion dogs have emerged as a powerful resource for better understanding human cancer. The genetic, molecular, and histological features of tumors in dogs are more closely related to those in humans than the ones in laboratory animals, including complex mechanisms of drug resistance.</p><p><strong>Methods: </strong>A comprehensive literature search was conducted in the electronic database Clarivate Web of Science (WOS): Medical Literature Analysis and Retrieval System Online (MEDLINE) from 1990 to 2025 (updated 22 January 2025). The final set includes 59 relevant full-text English articles.</p><p><strong>Results: </strong>The literature findings suggest that canine spontaneous tumors are valuable model systems with important translational implications for identifying novel mechanisms of chemotherapy resistance shared with humans and may help advance the current standard of care in precision medicine.</p><p><strong>Conclusions: </strong>We have provided an updated overview of the role of canine tumor models to study oncotherapy resistance, focusing on limitations and opportunities for advancement. Despite complementary benefits of such models in translational oncology research, their relevance remains underestimated. Strengthening the collaboration between human and veterinary medicine professionals and comparative medicine researchers, and obtaining the support of interdisciplinary institutions, could contribute to addressing the problem of multidrug resistance for both human and canine patients. Future research may promote using canine spontaneous tumors as translational therapeutic models for human chemoresistance, through a multidisciplinary approach based on the emerging \"One Health, One Medicine\" paradigm.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 12","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12191360/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144494825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to Tjalma, W.A. Comment on \"Gentile et al. Superior Survival and Lower Recurrence Outcomes with Breast-Conserving Surgery Compared to Mastectomy Following Neoadjuvant Therapy in 607 Breast Cancer Patients. <i>Cancers</i> 2025, <i>17</i>, 766\".","authors":"Damiano Gentile, Jacopo Canzian, Erika Barbieri, Simone Di Maria Grimaldi, Rita De Sanctis, Corrado Tinterri","doi":"10.3390/cancers17122009","DOIUrl":"10.3390/cancers17122009","url":null,"abstract":"<p><p>We would like to thank Dr [...].</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 12","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12190720/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144494853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}